|
|
Volumn 7, Issue 27, 2016, Pages 41612-41621
|
|
Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options
a a a a a |
|
Author keywords
immunohistochemistry; MTORC2; rapalog therapy; renal cell carcinoma; resistance
|
|
Indexed keywords
EVEROLIMUS;
MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2;
MITOGEN ACTIVATED PROTEIN KINASE;
ONCOPROTEIN;
RAPAMYCIN;
STAT3 PROTEIN;
STAT3 PROTEIN, HUMAN;
TEMSIROLIMUS;
ANALOGS AND DERIVATIVES;
APOPTOSIS;
BIOLOGY;
CELL SIZE;
CELL SURVIVAL;
DISEASE EXACERBATION;
DRUG EFFECTS;
DRUG RESISTANCE;
ENZYME ACTIVATION;
GENE EXPRESSION PROFILING;
HUMAN;
KIDNEY TUMOR;
MAPK SIGNALING;
METABOLISM;
METASTASIS;
PATHOLOGY;
PHYSIOLOGY;
PROCEDURES;
PROTEOMICS;
RENAL CELL CARCINOMA;
SIGNAL TRANSDUCTION;
TUMOR VOLUME;
APOPTOSIS;
CARCINOMA, RENAL CELL;
CELL SIZE;
CELL SURVIVAL;
COMPUTATIONAL BIOLOGY;
DISEASE PROGRESSION;
DRUG RESISTANCE, NEOPLASM;
ENZYME ACTIVATION;
EVEROLIMUS;
EXTRACELLULAR SIGNAL-REGULATED MAP KINASES;
GENE EXPRESSION PROFILING;
HUMANS;
KIDNEY NEOPLASMS;
MAP KINASE SIGNALING SYSTEM;
MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 2;
NEOPLASM METASTASIS;
ONCOGENE PROTEIN V-AKT;
PROTEOMICS;
SIGNAL TRANSDUCTION;
SIROLIMUS;
STAT3 TRANSCRIPTION FACTOR;
TUMOR BURDEN;
|
|
EID: 85014385550
PISSN: None
EISSN: 19492553
Source Type: Journal
DOI: 10.18632/oncotarget.9508 Document Type: Article |
|
Times cited : (12)
|
|
References (0)
|